Clinical studies are an important part of drug development globally. The number of registered clinical trials has increased significantly recently. As of November 8, 2024, there were over 515 thousand clinical studies registered globally. The number of clinical studies has increased significantly since there were just 2,119 registered in 2000. In general, clinical trials have grown more complex in recent years and remain vital for the research and development of new drugs and products. Research and development Research and development are an important part of pharmaceutical companies and includes drug development and product development. Among all industry sectors, the pharmaceutical industry spends the largest percentage of their revenue on research and development. Many companies are active in pharmaceutical research and development globally. It is projected Swiss company Roche will remain one of the largest research and development spenders among pharmaceutical companies in the near future. Clinical studies globally Most clinical studies occurring globally are held in countries outside of the U.S. Many clinical trials performed outside the U.S. and EU are done so because it is often easier and cheaper to conduct trials in other locations. Success rates for clinical trials depend heavily on the stage of the trial and the drugs or products being developed. Recent data suggested that only around 29 percent of drugs make it from phase II to phase III.

This data package contains datasets on clinical trials conducted in the United States. Diseases include cervical cancer, diabetes, acute respiratory infection as well as stress. This data package also includes clinical trials registry and results database.

As of November 8, 2024, the number of registered clinical studies in non-U.S. regions stood at some 284 thousand - or 55 percent of all studies worldwide. This statistic shows the distribution of registered clinical studies worldwide by location.

BackgroundIn medical practice, clinically unexpected measurements might be quite properly handled by the remeasurement, removal, or reclassification of patients. If these habits are not prevented during clinical research, how much of each is needed to sway an entire study?Methods and ResultsBelieving there is a difference between groups, a well-intentioned clinician researcher addresses unexpected values. We tested how much removal, remeasurement, or reclassification of patients would be needed in most cases to turn an otherwise-neutral study positive. Remeasurement of 19 patients out of 200 per group was required to make most studies positive. Removal was more powerful: just 9 out of 200 was enough. Reclassification was most powerful, with 5 out of 200 enough. The larger the study, the smaller the proportion of patients needing to be manipulated to make the study positive: the percentages needed to be remeasured, removed, or reclassified fell from 45%, 20%, and 10% respectively for a 20 patient-per-group study, to 4%, 2%, and 1% for an 800 patient-per-group study. Dot-plots, but not bar-charts, make the perhaps-inadvertent manipulations visible. Detection is possible using statistical methods such as the Tadpole test.ConclusionsBehaviours necessary for clinical practice are destructive to clinical research. Even small amounts of selective remeasurement, removal, or reclassification can produce false positive results. Size matters: larger studies are proportionately more vulnerable. If observational studies permit selective unblinded enrolment, malleable classification, or selective remeasurement, then results are not credible. Clinical research is very vulnerable to “remeasurement, removal, and reclassification”, the 3 evil R's.

In 2021, 27 percent of all clinical drug trials worldwide were started in North America, whereas 30 percent of trials were initiated in Asia. This statistic shows the geographical distribution of clinical drug trials started worldwide from 2012 to 2022, by region.

Website which allows data from completed clinical trials to be distributed to investigators and public. Researchers can download de-identified data from completed NIDA clinical trial studies to conduct analyses that improve quality of drug abuse treatment. Incorporates data from Division of Therapeutics and Medical Consequences and Center for Clinical Trials Network.

The Health Statistics and Health Research Database is Estonian largest set of health-related statistics and survey results administrated by National Institute for Health Development. Use of the database is free of charge.

The database consists of eight main areas divided into sub-areas. The data tables included in the sub-areas are assigned unique codes. The data tables presented in the database can be both viewed in the Internet environment, and downloaded using different file formats (.px, .xlsx, .csv, .json). You can download the detailed database user manual here (.pdf).

The database is constantly updated with new data. Dates of updating the existing data tables and adding new data are provided in the release calendar. The date of the last update to each table is provided after the title of the table in the list of data tables.

A contact person for each sub-area is provided under the "Definitions and Methodology" link of each sub-area, so you can ask additional information about the data published in the database. Contact this person for any further questions and data requests.

Read more about publication of health statistics by National Institute for Health Development in Health Statistics Dissemination Principles.

This statistic shows weighted averages of clinical trial costs by selected cost component and clinical phase, as of 2014. The clinical trial cost for the cost component of Data Management in Phase I was 50,331 U.S. dollars as of that year.

Objective: To explore the structure and content of a non-random sample of clinical study reports (CSRs) to guide clinicians and systematic reviewers. Search strategy: We searched public sources and lodged Freedom of Information requests for previously confidential CSRs primarily written by industry for regulators. Selection criteria: CSR reporting sufficient information for extraction ("adequate"). Primary outcome measures: Presence and length of essential elements of trial design and reporting and compression factor (ratio of page length for CSR compared to its published counterpart in a scientific journal). Data extraction: data were extracted on standard forms and cross-checked for accuracy. Results: We assembled a population of 78 CSRs (covering 90 RCTs; 144,610 pages total) dated 1991-2011 of 14 pharmaceuticals. Report synopses had a median length of 5 pages, efficacy evaluation 13.5 pages, safety evaluation 17 pages, attached tables 337 pages, trial protocol 62 pages, statistical analysis plan 15 pages, and individual efficacy and safety listings had a median length of 447 and 109.5 pages, respectively. While 16 (21%) of CSRs contained completed case report forms, these were accessible to us in only one case (765 pages representing 16 individuals). Compression factors ranged between 1 and 8805. Conclusions: Clinical study reports represent a hitherto mostly hidden and untapped source of detailed and exhaustive data on each trial. They should be consulted by independent parties interested in a detailed record of a clinical trial, and should form the basic unit for evidence synthesis as their use is likely to minimize the problem of reporting bias. We cannot say whether our sample is representative and whether our conclusions are generalizable to an undefined and undefineable population of CSRs.

This statistic depicts the percentage of clinical trial participants that had select reasons for participating in the clinical trials as of 2019. According to the data, 43 percent of participants participated to help advance science and the treatment of their disease or condition.

Quality scoring components for 8 clinical trials included.

The following is an information retrieval test collection that contains:

• 204,855 publicly available clinical trails was crawled from ClinicalTrials.gov.
• 60 topics made up of three types: patient case descriptions, patient case summaries and assessor provided ad-hoc queries, totalling an average of 10.2 queries per topic.
• 4,000 assessor provided relevance assessment for topic, trial pairs.

Further details about the test collection can be found in the following publication:

B. Koopman and G. Zuccon. A test collection for matching patient trials. In Proceedings of the 39th annual international ACM SIGIR conference on research and development in information retrieval, Pisa, July 2016.

Background and PurposeSpontaneous intracerebral hemorrhage (ICH) is a devastating form of stroke with a poor prognosis overall. We conducted a systematic review and meta-analysis to identify and describe factors associated with early neurologic deterioration (END) after ICH.MethodsWe sought to identify any factor which could be prognostic in the absence of an intervention. The Cochrane Library, EMBASE, the Global Health Library, and PubMed were searched for primary studies from the years 1966 to 2012 with no restrictions on language or study design. Studies of patients who received a surgical intervention or specific experimental therapies were excluded. END was defined as death, or worsening on a reliable outcome scale within seven days after onset.Results7,172 abstracts were reviewed, 1,579 full-text papers were obtained and screened. 14 studies were identified; including 2088 patients. Indices of ICH severity such as ICH volume (univariate combined OR per ml:1.37, 95%CI: 1.12–1.68), presence of intraventricular hemorrhage (2.95, 95%CI: 1.57–5.55), glucose concentration (per mmol/l: 2.14, 95%CI: 1.03–4.47), fibrinogen concentration (per g/l: 1.83, 95%CI: 1.03–3.25), and d-dimer concentration at hospital admission (per mg/l: 4.19, 95%CI: 1.88–9.34) were significantly associated with END after random-effects analyses. Whereas commonly described risk factors for ICH progression such as blood pressure, history of hypertension, and ICH growth were not.ConclusionsThis study summarizes the evidence to date on early ICH prognosis and highlights that the amount and distribution of the initial bleed at hospital admission may be the most important factors to consider when predicting early clinical outcomes.

This metadata describes the data format for data contributions to the International COVID-19 Data Alliance (ICODA) driver project investigating the safety and efficacy of clinical trials. The first data dictionary was published in December 2020, newer versions are available.

Several thousand clinical COVID-19 trials were in progress globally. As these trials were all evaluating the benefit/risk of potential COVID-19 treatment options, it was vital that the scientific community could interrogate this data as it emerged.

The summary level data from some of these trials across industry, academia and government was included in the ICODA Workbench. In order to provide near-immediate access to results and data from the trials, ICODA has partnered with Certara to provide curated and digitised summary level data from key trials as they were reported in the public domain. In addition, several data contributing organisations provided enriched summary-level data within 5-30 days post top-line reporting of the trial results which allowed a more in depth evaluation of the results.

This Driver project used a Data Dictionary to harmonise variable definitions and subgroup classifications from all trials. This allowed side by side interrogation of the data from these trials making the data readily useable to interpret findings. Researchers could also view data from individual trials in the context of other available trials thus expanding their insights. Our visual analytics and meta-analyses tools further enhanced the researchers’ ability to work quickly.

clinicaltrials.gov_searchThis is complete original dataset.identify completed trialsThis is the R script which when run on "clinicaltrials.gov_search.txt" will produce a .csv file which lists all the completed trials.FDA_table_with_sensThis is the final dataset after cross referencing the trials. An explanation of the variables is included in the supplementary file "2011-10-31 Prayle Hurley Smyth Supplementary file 3 variables in the dataset".analysis_after_FDA_categorization_and_sensThis R script reproduces the analysis from the paper, including the tables and statistical tests. The comments should make it self explanatory.2011-11-02 prayle hurley smyth supplementary file 1 STROBE checklistThis is a STROBE checklist for the study2011-10-31 Prayle Hurley Smyth Supplementary file 2 examples of categorizationThis is a supplementary file which illustrates some of the decisions which had to be made when categorizing trials.2011-10-31 Prayle Hurley Smyth Supplementary file 3 variables in th...

PRISMA Checklist. (DOC)

E-Clinical Solutions Market size was valued at USD 6.5 Billion in 2023 and is projected to reach USD 15.2 Billion by 2031, growing at a CAGR of 11.2% from 2024 to 2031.

Key Market Drivers
• Rising Demand for Clinical Trials Efficiency: With increasing drug discovery and development, the need for faster and more efficient clinical trials is growing fueling demand for e-clinical solutions.
• Advancements in Healthcare IT: The growing integration of healthcare IT solutions is driving the adoption of advanced clinical management tools.
• Regulatory Pressure: Stricter regulatory requirements for clinical trials, particularly regarding data accuracy and patient safety, are pushing for the adoption of e-clinical solutions.
• Increasing Outsourcing to CROs: Contract Research Organizations (CROs) are increasingly using e-clinical tools to manage outsourced clinical trials, further boosting market growth.

The National Database for Clinical Trials Related to Mental Illness (NDCT) is an extensible informatics platform for relevant data at all levels of biological and behavioral organization (molecules, genes, neural tissue, behavioral, social and environmental interactions) and for all data types (text, numeric, image, time series, etc.) related to clinical trials funded by the National Institute of Mental Health. Sharing data, associated tools, methodologies and results, rather than just summaries or interpretations, accelerates research progress. Community-wide sharing requires common data definitions and standards, as well as comprehensive and coherent informatics approaches for the sharing of de-identified human subject research data. Built on the National Database for Autism Research (NDAR) informatics platform, NDCT provides a comprehensive data sharing platform for NIMH grantees supporting clinical trials.

This dataset is about books and is filtered where the author includes Ton J. M. Cleophas and the book includes Modern Bayesian statistics in clinical research, featuring 7 columns including author, BNB id, book, book publisher, and ISBN. The preview is ordered by publication date (descending).